MA Social Media Communications- @DCU Alumni Account Executive @TrophicComms Full-time writer, part-time daydreamer

München, DE
Joined May 2021
Well said... an investment in #diversity provides access to a wealth of untapped potential & future opportunities to innovate
Heard at @LS_Cares Impact Breakfast: “If we can invest 13 years in developing a drug, we must invest 13 years in developing girls with an interest in STEM”. +100%
2
“In the last two-to-three years, the whole biotech environment has changed dramatically. In America, until last year, there were a lot of companies going public, and they didn’t need to do deals, so it was all on their own terms" biocentury.com/article/64314…
1
While the pace of new #SPAC offerings seem to have slowed in the second quarter of 2021, they are still positioned as an attractive option for private #biotech & #pharma companies in need of rapid access to capital thepharmaletter.com/article/…
So excited that I finally get to unveil my first solo website project. Thank you to the @TrophicComms team for trusting me to see it through and thank you to Ante and his team at @imagemakersmuc for helping me bring the vision to life.
Our newly updated website is finally here! A big thank you to our long-term collaborator, @imagemakersmuc, for bringing our vision to life. Check out trophic.eu/ to learn more about our capabilities as a strategic corporate #communications partner in the #lifesciences
Check out this great article from Labiotech.eu on how companies such as @OsivaxVaccines are leading the charge in generating #universalvaccines that can protect the population from all current and future strands of #Covid19. labiotech.eu/trends-news/eme…
1
#Drugregulations present major challlenges for EU companies hoping for success in the US market. companies require a keen #commercialisation strategy, customizable to the needs of your specific drug. Check out this insightful piece in @pharmaphorum bit.ly/3l4jTq8
So happy to be apart of this amazing team of communicators and celebrate Trophic's 4th #anniversary. I look forward to what the next year has in store!
Replying to @TrophicComms
And of course we can not celebrate without one of our famous anniversary cakes!
3
A great article by @VirginiaGewin about the online initiative recognizing the contributions of black scientists and their increasing roles within the various areas of clinical research. Very proud to be #BlackinBiotech #diversity #inclusion
Five researchers who organized and took part in the #BlackinSTEM weeks discuss their movements' impacts and rewards, including career opportunities, collaborations and meaningful institutional actions. go.nature.com/3su8z9i
2
Desmond James retweeted
“When you’re the VC, you’re kind of the kingmaker ... I felt like the entrepreneur needed someone to reach their hand out and say, ‘I’m going to help you with this.’” -- @cngarabedian. This week, @BosBizRowan reports on biotech's new funding models: bizjournals.com/boston/news/…
1
4
15
Great Article on how scientists and farmers are using social media to combat #misinformation posts. Platforms such as LinkedIn and Twitter can be valuable tools for #biotech professionals. bit.ly/3jbca7L
1
3
In the wake of the Covid-19 pandemic, companies like @immatics were able to launch successful #IPOlistings, proving there is keen interest from investors in the #biotech space. Checkout the Labiotech.eu article on whether this "trend" is potentially just the beginning
With record amounts of cash flowing into the #biotech industry, it’s natural to wonder when the funding window will close. According to Simon Goldman, @UCLTF's Investment Director, there’s little reason to assume this window will close at all. Here's why 👇🏻loom.ly/eDqBFEQ
1
As companies within the #biotech and #LifeSciences sectors start planning for their next fundraising efforts, the need for a firm like with #InvestorRelations capabilities like @TrophicComms is crucial.
We provide a range of #IR services, from run-up to #IPO & #investor targeting based on peer analysis, to presentation training & developing financial communications. Visit trophic.eu for more on our IR/PR capabilities. #LifeSciences
Today the #FDA determines the approval of #Aducanumab. @nytimes published a piece addressing the drug's pros and cons and two other treatment options that are showing promising data in case it is not approved. nytimes.com/2021/06/05/healt…
Covid-19 has forced many startups to change course in favor of funding, highlighting the importance of #telehealth within the #biotech space. Machine Learning has become a necessary digital tool towards ensuring business continuity. labiotech.eu/interview/europ…
1
1